10/11/24

Survey: Grass pollen allergy sufferers wanted!

For all those who want to support our research work. It is only possible to fill in the questionnaire until Tuesday next week!

We need your help!
Survey: Grass pollen allergy sufferers wanted!
We are looking for adult men and women with a grass pollen allergy who would like to take part in a 5-minute anonymous online survey.

The be-all and end-all for every allergy sufferer is allergen avoidance. Our aim is to make this task as easy as possible for all Austrians. In most cases, however, allergen avoidance is not enough and medication is used to alleviate symptoms, such as antihistamines (allergy tablets), anti-allergic nose and eye drops or nasal sprays containing cortisone (etc.). However, in order to get to the root of the problem, immunotherapy is the only form of therapy which, in contrast to symptomatic therapies, addresses the cause of the disease and can therefore achieve a lasting improvement in allergy symptoms (allergy complaints).
Research is constantly being carried out to improve allergy therapies in order to improve the lives of allergy sufferers. We support this research and would therefore like to ask you to give us your valuable time for the benefit of all pollen allergy sufferers.
What we need from you:
We are looking for adult men and women with a grass pollen allergy who would like to take part in an anonymous online survey lasting approximately 5 minutes.

To participate, please click on the following link:

https://forms.office.com/e/3dhJa1n8zs?origin=lprLink

The aim of the survey is to ask you, as an allergy sufferer, what relief from your allergy symptoms (such as watery/itchy/reddened eyes, blocked/runny nose or sneezing) you would like from an allergy therapy with a long-lasting effect.

Your answer will help us to better understand the therapeutic goals of pollen allergy sufferers.
Important note on data protection: This is an anonymous online survey, NO personal data will be requested, processed or stored!

Thank you very much for your support!

Go to news overview
Loading...